Protocol Benchmark Radar
Benchmark public-trial design patterns by endpoint, eligibility burden, biomarker strategy, background therapy, and operational risk.
Built from public trial registry text. Signals reflect what is visible in ClinicalTrials.gov — not recommendations for endpoints, treatment strategies, or regulatory paths.
How does a protocol compare with recent public trial precedent?
Whether a team is designing a Phase 2 protocol, evaluating a competitor's trial, or reviewing a licensing candidate, Protocol Benchmark Radar converts public trial records into structured precedent signals — endpoint patterns, eligibility burden, biomarker usage, and design differentiation.
Target users
- Biotech clinical-development teams planning or benchmarking protocols
- CRO feasibility teams evaluating recruitment burden and design risk
- Clinical consultants supporting protocol review and diligence
- Investors evaluating trial design quality and competitive context
- Translational medicine groups bridging mechanism and design decisions
- Autoimmune and immunology teams building indication-specific precedent
What Protocol Benchmark Radar analyzes
- Primary and secondary endpoints
- Eligibility criteria and enrollment burden
- Biomarker and subgroup usage
- Comparator and background therapy patterns
- Trial duration and follow-up structure
- Operational and recruitment risk signals
- Design differentiation labels
- Patent-related design signals (optional appendix)
How teams use this module
- Benchmark lupus nephritis endpoints against recent public trial precedent
- Compare eligibility burden across trials to identify restrictive versus permissive designs
- Detect restrictive recruitment criteria that may slow enrollment
- Map biomarker-enriched designs and subgroup usage patterns
- Evaluate whether a proposed trial design is conventional or differentiated
- Support Phase 2 protocol planning and BD diligence review
Lupus Nephritis Protocol Benchmark
Benchmark public lupus nephritis trial designs by endpoint precedent, eligibility burden, biomarker strategy, comparator/background therapy, and operational risk.
- Endpoint and eligibility benchmark signals
- Biomarker and subgroup usage map
- Comparator/background therapy patterning
- Source-linked trial detail pages
Receive Benchmark Updates by Email
Subscribe to receive benchmark updates by email, choose CSV interests, and tell us if you want a custom protocol benchmarking follow-up for another indication.